Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilpivirine - Janssen R&D Ireland

Drug Profile

Rilpivirine - Janssen R&D Ireland

Alternative Names: Edurant; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rilpivirine hydrochloride; TMC 278; TMC-278-A; TMC278 LA (IM injection) - Tibotec; TMC278LA

Latest Information Update: 25 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen Therapeutics; PATH
  • Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 09 Jul 2019 Janssen Research & Development plans a phase II trial in HIV-1 infections (In children) in Italy, Portugal, Romania, South Africa, Spain Thailand, Uganda (NCT04012931; EudraCT2018-004301-32)
  • 20 Feb 2019 Janssen Sciences initiates an expanded-access programme for HIV-1 infections in Ireland (IM) (NCT03847376)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in Belgium (PO, Granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top